ロード中...
Pirfenidone and Nintedanib in idiopathic pulmonary fibrosis: Real-life experience in an Italian referral centre
Background: Idiopathic pulmonary fibrosis has a median survival time after diagnosis of 2–5 years. The main goal of treating IPF is to stabilize or reduce the rate of disease progression. Nintedanib and Pirfenidone have been a breakthrough in the management of IPF. Here we evaluated the effectivenes...
保存先:
| 主要な著者: | , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier España
2019-05-01
|
| シリーズ: | Pulmonology |
| オンライン･アクセス: | http://www.sciencedirect.com/science/article/pii/S2531043718300990 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|